Co-Delivery of Minoxidil and Finasteride via Ionic Liquid and Cyclodextrin-Assisted In Situ Thermosensitive Hydrogel for Synergistic Treatment of Androgenic Alopecia

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

The researchers reported that a newly developed ionic liquid-based microemulsion significantly improved the local delivery of copper peptides in mice, enhancing hair growth-related factor activation while offering a safer, non-invasive alternative to existing treatments for hair loss.

In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This study reported that a novel vasodilator drug called TOP-M119, when delivered using a specially designed dissolving microneedle system, showed enhanced targeting of hair follicles and effectiveness in treating alopecia, demonstrated through in vitro, ex vivo, and in vivo studies involving mouse skin.

This study found that a ceria nanozyme-integrated microneedles patch accelerated hair regeneration in an androgenetic alopecia mouse model more effectively than minoxidil, with reduced application frequency and minimal skin damage.

This study found that KY19382 can effectively promote hair regeneration and follicle neogenesis in mice and human hair models by activating Wnt/β-catenin signalling, suggesting potential use for alopecia treatment.

This commentary reviews the evidence for microinflammation's role in pattern hair loss and suggests that further studies with age- and sex-matched controls are needed to substantiate the findings.

Finasteride and baicalin in phospholipid vesicles effectively promote hair growth and increase follicle count.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study found that treatment with the polyphenolic compound TCQA activated β-catenin, promoting hair regrowth and the initiation of the anagen phase in mice and human dermal papilla cells.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This research investigated aqueous alginate-based hydrogels for delivering minoxidil and reported that using hydroxypropyl-β-cyclodextrin (HP-β-CD) with molar substitution 0.65 significantly enhanced minoxidil's solubility and skin permeability without damaging the epidermis, suggesting potential as an alternative to commercial minoxidil solutions.

This study found that the dimethyl-β-cyclodextrin inclusion system significantly improved the solubility and bioavailability of finasteride compared to the drug alone, enhancing its absorption rate.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This paper discusses the adverse effects of finasteride, including sexual dysfunction and depression, and suggests that treatment customization based on individual factors like hand preference and sexual orientation could improve outcomes and reduce these side effects.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This study found that minoxidil applied to a damp scalp may increase drug penetration in vitro, potentially improving treatment effectiveness.

This study found that apoptosis was more prevalent in hair follicles of women with female pattern hair loss, particularly in miniaturized follicles, and was associated with follicular inflammation.

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study found that VEGF stimulates the proliferation of human hair follicle dermal papilla cells via the VEGFR-2/ERK pathway, without involving p38, JNK, or AKT signaling.

IL-6 contributes to hair loss by shortening the growth phase and causing hair follicles to regress.

This review discusses recent advancements in hair rejuvenation strategies and assesses the potential of herbal drugs as safer alternatives, but reports no new clinical results.

This review summarizes recent advances in understanding the molecular mechanisms of hair follicle formation and discusses potential future clinical applications for treating hair loss and skin tumors, but it reports no new clinical results.

Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.

This study introduces the concept of teloptosis, which influences hair shedding during the telogen phase and affects hair density, highlighting that early or delayed teloptosis has noticeable effects.